| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44d44b84cf275e3d14443f41a06d5419
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2647781193636ae95d1f745755a9a7f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-94 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2008-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5364b698062d16e2c349d4509b66d0d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f0200a146a80485b46cd770cfea560a |
| publicationDate |
2009-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009325918-A1 |
| titleOfInvention |
Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action |
| abstract |
Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone have fewer effects mediated by gonadal steroid receptors relative to effect mediated by minteralocorticoid progesterone receptors, compared to the stereoisomerically unpurified form of the compound. These optically active compounds can be useful for obtaining reduction in moderate essential hypertension and it the treatment of congestive heart failure in humans with minimized undesirable side effects such as gynecomastia, tender breast enlargement and menstrual irregularities in women, and loss of libido in men. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10350223-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016141182-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112390843-A |
| priorityDate |
2008-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |